23 Jun 2020 15:07
Tissue Regenix Group Plc
("Tissue Regenix" or the "Company")
PDMR dealing and issue of equity
Leeds, 23 June 2020- Tissue Regenix Group plc (AIM:TRX), the regenerative medical devices company, announces the exercise of options by Shervanthi Homer-Vanniasinkam, a Non-Executive Director.
In consequence of the exercise of options, the Company has issued and allotted 1,388,222 ordinary shares of 0.1p each in the Company (the "Option Shares") at an exercise price of 0.00456p pence per share. The Option Shares will rank pari passu with the existing ordinary shares. An application has been made for the Option Shares to be admitted to trading on AIM which is expected to take place at 8:00am on or around 29 June 2020.
Following the issue of the Option Shares, Ms Homer-Vanniasinkam will be interested in a total of 1,638,222 shares in the Company representing 0.02% of the enlarged issued share capital.
Total voting rights
Following the issue of the 1,388,222 new ordinary shares, the Company will have a total of 7,032,985,756 ordinary shares of 0.1p each in issue. The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For more Information:
Tissue Regenix Group plc Caitlin Pearson, Head of Communications |
Tel: 0330 430 3073 |
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Jonathan Senior / Alex Price / Ben Maddison | Tel: 0207 710 7600
|
|
|
FTI Consulting Simon Conway / Victoria Foster Mitchell / Mary Whittow | Tel: 0203 727 1000 |
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.
Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.
1
| Details of the person discharging managerial responsibilities / person closely associated | |
a)
| Names | Shervanthi Homer-Vanniasinkam |
2
| Reason for the notification | |
a)
| Position/status
| Non-Executive Director |
b)
| Initial notification /Amendment
| Initial notification |
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a)
| Name
| Tissue Regenix Group plc |
b)
| LEI | 213800PNOD5UHQUFJI36 |
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a)
| Description of the financial instrument, type of instrument
| Ordinary Shares of 0.1p |
b) | Identification code
| GB00B5SGVL29 |
c)
| Nature of the transaction
| Exercise of options over Ordinary Shares |
d)
| Price(s) and volume(s) | Volume(s): 1,388,222 Ordinary Shares Price: 0.00456 pence per Ordinary Share |
d)
| Aggregated information - Aggregated volume - Price | N/A
|
e)
| Date of the transactions | 23 June 2020 |
f)
| Place of the transaction | Outside of a trading venue |
Tissue Regenix Group (TRX)